Morgan Stanley Maintains a Hold on Pfizer (PFE)

Pfizer Inc. (NYSE:PFE) is one of the best cheap stocks under $50 to buy now. On July 10, Morgan Stanley analyst Terrence Flynn reiterated a hold rating on Pfizer Inc. (NYSE:PFE), setting a $32 price target.

Pfizer’s Dividend Backed by Strong Free Cash Flow

A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution.

The company declared a $0.43 fiscal Q3 2025 dividend on June 25 on its common stock, payable September 2 to holders of record at the close of business on July 25. The fiscal Q3 2025 cash dividend marks Pfizer Inc.’s (NYSE:PFE) 347th consecutive quarterly dividend.

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets.

While we acknowledge the potential of PFE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.